Late-fluorescence mammography assesses tumor capillary permeability and differentiates malignant from benign lesions

Axel Hagen; Dirk Grosenick; Rainer Macdonald; Herbert Rinneberg; Susen Burock; Peter Warnick; Alexander Poellinger; Peter M. Schlag

doi:10.1364/OE.17.017016

Late-fluorescence mammography assesses tumor capillary permeability and differentiates malignant from benign lesions

Axel Hagen, Dirk Grosenick, Rainer Macdonald, Herbert Rinneberg, Susen Burock, Peter Warnick, Alexander Poellinger, and Peter M. Schlag

Optics Express
Vol. 17,
Issue 19,
pp. 17016-17033
(2009)
•https://doi.org/10.1364/OE.17.017016

Get Citation
Copy Citation Text
Axel Hagen, Dirk Grosenick, Rainer Macdonald, Herbert Rinneberg, Susen Burock, Peter Warnick, Alexander Poellinger, and Peter M. Schlag, "Late-fluorescence mammography assesses tumor capillary permeability and differentiates malignant from benign lesions," Opt. Express 17, 17016-17033 (2009)

Export Citation
- BibTex
- Endnote (RIS)
- HTML
- Plain Text
Get PDF (412 KB)
Set citation alerts
Save article

Related Topics
Table of Contents Category
- Medical Optics and Biotechnology
Optics & Photonics Topics
?

The topics in this list come from the OSA Optics and Photonics Topics applied to this article.
Previously assigned OCIS codes
- Mammography (170.3830)
- Spectroscopy, fluorescence and luminescence (170.6280)
- Fluorescence (260.2510)

About this Article
History
- Original Manuscript: July 8, 2009
- Revised Manuscript: August 20, 2009
- Manuscript Accepted: August 24, 2009
- Published: September 9, 2009
Virtual Issues
Virtual Journal for Biomedical Optics Vol. 4, Iss. 11

Accessible

Open Access

Abstract

Using scanning time-domain instrumentation we recorded fluorescence projection mammograms on few breast cancer patients prior, during and after infusion of indocyanine green (ICG), while monitoring arterial ICG concentration by transcutaneous pulse densitometry. Late-fluorescence mammograms recorded after ICG had been largely cleared from the blood by the liver, showed invasive carcinomas at high contrast over a rather homogeneous background, whereas benign lesions did not produce (focused) fluorescence contrast. During infusion, tissue concentration contrast and hence fluorescence contrast is determined by intravascular contributions, whereas late-fluorescence mammograms are dominated by contributions from protein-bound ICG extravasated into the interstitium, reflecting relative microvascular permeabilities of carcinomas and normal breast tissue. We simulated intravascular and extravascular contributions to ICG tissue concentration contrast within a two-compartment unidirectional pharmacokinetic model.

Full Article | PDF Article

OSA Recommended Articles

Three-dimensional time-resolved optical mammography of the uncompressed breast

Louise C. Enfield, Adam P. Gibson, Nicholas L. Everdell, David T. Delpy, Martin Schweiger, Simon R. Arridge, Caroline Richardson, Mohammad Keshtgar, Michael Douek, and Jeremy C. Hebden
Appl. Opt. 46(17) 3628-3638 (2007)

In vivo quantification of optical contrast agent dynamics in rat tumors by use of diffuse optical spectroscopy with magnetic resonance imaging coregistration

David J. Cuccia, Frederic Bevilacqua, Anthony J. Durkin, Sean Merritt, Bruce J. Tromberg, Gultekin Gulsen, Hon Yu, Jun Wang, and Orhan Nalcioglu
Appl. Opt. 42(16) 2940-2950 (2003)

Time-domain optical mammography: initial clinical results on detection and characterization of breast tumors

Dirk Grosenick, K. Thomas Moesta, Heidrun Wabnitz, Jörg Mucke, Christian Stroszczynski, Rainer Macdonald, Peter M. Schlag, and Herbert Rinneberg
Appl. Opt. 42(16) 3170-3186 (2003)

References

View by:
Article Order
|
Year
|
Author
|
Publication

A. Cerussi, N. Shah, D. Hsiang, A. Durkin, J. Butler, and B. J. Tromberg, “In vivo absorption, scattering, and physiologic properties of 58 malignant breast tumors determined by broadband diffuse optical spectroscopy,” J. Biomed. Opt. 11(4), 044005 (2006).
[PubMed]
A. Cerussi, D. Hsiang, N. Shah, R. Mehta, A. Durkin, J. Butler, and B. J. Tromberg, “Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy,” Proc. Natl. Acad. Sci. U.S.A. 104(10), 4014–4019 (2007).
[PubMed]
C. Zhou, R. Choe, N. Shah, T. Durduran, G. Yu, A. Durkin, D. Hsiang, R. Mehta, J. Butler, A. Cerussi, B. J. Tromberg, and A. G. Yodh, “Diffuse optical monitoring of blood flow and oxygenation in human breast cancer during early stages of neoadjuvant chemotherapy,” J. Biomed. Opt. 12(5), 051903 (2007).
[PubMed]
M. A. Franceschini, K. T. Moesta, S. Fantini, G. Gaida, E. Gratton, H. Jess, W. W. Mantulin, M. Seeber, P. M. Schlag, and M. Kaschke, “Frequency-domain techniques enhance optical mammography: initial clinical results,” Proc. Natl. Acad. Sci. U.S.A. 94(12), 6468–6473 (1997).
[PubMed]
L. Götz, S. H. Heywang-Köbrunner, O. Schütz, and H. Siebold, “Optical mammography on preoperative patients (Optische Mammographie an präoperativen Patientinnen),” Akt. Radiol. 8, 31–33 (1998).
S. B. Colak, M. B. van der Mark, G. W. 't Hooft, J. H. Hoogenraad, E. S. van der Linden, and F. A. Kuijpers, “Clinical optical tomography and NIR spectroscopy for breast cancer detection,” IEEE J. Sel. Top. Quantum Electron. 5(4), 1143–1158 (1999).
H. Dehghani, B. W. Pogue, S. P. Poplack, and K. D. Paulsen, “Multiwavelength three-dimensional near-infrared tomography of the breast: initial simulation, phantom, and clinical results,” Appl. Opt. 42(1), 135–145 (2003).
[PubMed]
P. Taroni, A. Torricelli, L. Spinelli, A. Pifferi, F. Arpaia, G. Danesini, and R. Cubeddu, “Time-resolved optical mammography between 637 and 985 nm: clinical study on the detection and identification of breast lesions,” Phys. Med. Biol. 50(11), 2469–2488 (2005).
[PubMed]
D. Grosenick, K. Th. Moesta, M. Möller, J. Mucke, H. Wabnitz, B. Gebauer, Ch. Stroszczynski, B. Wassermann, P. M. Schlag, and H. Rinneberg, “Time-domain scanning optical mammography: I. Recording and assessment of mammograms of 154 patients,” Phys. Med. Biol. 50(11), 2429–2449 (2005).
[PubMed]
S. P. Poplack, T. D. Tosteson, W. A. Wells, B. W. Pogue, P. M. Meaney, A. Hartov, C. A. Kogel, S. K. Soho, J. J. Gibson, and K. D. Paulsen, “Electromagnetic breast imaging: results of a pilot study in women with abnormal mammograms,” Radiology 243(2), 350–359 (2007).
[PubMed]
H. Rinneberg, D. Grosenick, K. T. Moesta, H. Wabnitz, J. Mucke, G. Wübbeler, R. Macdonald, and P. Schlag, “Detection and characterization of breast tumours by time-domain scanning optical mammography,” Opto-Electronics Review 16(2), 147–162 (2008).
B. W. Pogue, S. C. Davis, X. Song, B. A. Brooksby, H. Dehghani, and K. D. Paulsen, “Image analysis methods for diffuse optical tomography,” J. Biomed. Opt. 11(3), 033001 (2006).
C. Perlitz, K. Licha, F. D. Scholle, B. Ebert, M. Bahner, P. Hauff, K. T. Moesta, and M. Schirner, “Comparison of two tricarbocyanine-based dyes for fluorescence optical imaging,” J. Fluoresc. 15(3), 443–454 (2005).
[PubMed]
R. Ziegler, Modeling photon transport and reconstruction of optical properties for performance assessment of laser und fluorescence mammographs and analysis of clinical data, Dissertation, Department of Physics, Free University of Berlin, Germany, 2008, ( http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000005928 ).
V. Ntziachristos, A. G. Yodh, M. Schnall, and B. Chance, “Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement,” Proc. Natl. Acad. Sci. U.S.A. 97(6), 2767–2772 (2000).
[PubMed]
X. Intes, J. Ripoll, Y. Chen, S. Nioka, A. G. Yodh, and B. Chance, “In vivo continuous-wave optical breast imaging enhanced with Indocyanine Green,” Med. Phys. 30(6), 1039–1047 (2003).
[PubMed]
A. Corlu, R. Choe, T. Durduran, M. A. Rosen, M. Schweiger, S. R. Arridge, M. D. Schnall, and A. G. Yodh, “Three-dimensional in vivo fluorescence diffuse optical tomography of breast cancer in humans,” Opt. Express 15(11), 6696–6716 (2007).
[PubMed]
P. Carmeliet and R. K. Jain, “Angiogenesis in cancer and other diseases,” Nature 407(6801), 249–257 (2000).
[PubMed]
A. L. Baert, K. Sartor, A. Jackson, D. L. Buckley, and G. J. M. Parker, eds., Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Oncology, Springer, Berlin, Heidelberg, Germany (2005).
H. Hashizume, P. Baluk, S. Morikawa, J. W. McLean, G. Thurston, S. Roberge, R. K. Jain, and D. M. McDonald, “Openings between defective endothelial cells explain tumor vessel leakiness,” Am. J. Pathol. 156(4), 1363–1380 (2000).
[PubMed]
D. Feng, J. A. Nagy, H. F. Dvorak, and A. M. Dvorak, “Ultrastructural studies define soluble macromolecular, particulate, and cellular transendothelial cell pathways in venules, lymphatic vessels, and tumor-associated microvessels in man and animals,” Microsc. Res. Tech. 57(5), 289–326 (2002).
[PubMed]
D. K. F. Meijer, B. Weert, and G. A. Vermeer, “Pharmacokinetics of biliary excretion in man. VI. Indocyanine green,” Eur. J. Clin. Pharmacol. 35(3), 295–303 (1988).
[PubMed]
P. Ott, L. Bass, and S. Keiding, “The kinetics of continuously infused indocyanine green in the pig,” J. Pharmacokinet. Biopharm. 24(1), 19–44 (1996).
[PubMed]
S. A. Carp, J. Selb, Q. Fang, R. Moore, D. B. Kopans, E. Rafferty, and D. A. Boas, “Dynamic functional and mechanical response of breast tissue to compression,” Opt. Express 16(20), 16064–16078 (2008).
[PubMed]
D. Grosenick, H. Wabnitz, H. H. Rinneberg, K. Th. Moesta, and P. M. Schlag, “Development of a time-domain optical mammograph and first in vivo applications,” Appl. Opt. 38(13), 2927–2943 (1999).
A. Hagen, O. Steinkellner, D. Grosenick, M. Möller, R. Ziegler, T. Nielsen, K. Lauritsen, R. Macdonald, and H. Rinneberg, “Development of a multi-channel time-domain fluorescence mammograph,” Proc. SPIE 6434, 64340Z (2007).
M. Möller, H. Wabnitz, A. Kummrow, D. Grosenick, A. Liebert, B. Wassermann, R. Macdonald, and H. Rinneberg, “A four-wavelength multi-channel scanning time-resolved optical mammograph,” Proc. SPIE 5138, 290–297 (2003).
D. J. Cuccia, F. Bevilacqua, A. J. Durkin, S. Merritt, B. J. Tromberg, G. Gulsen, H. Yu, J. Wang, and O. Nalcioglu, “In vivo quantification of optical contrast agent dynamics in rat tumors by use of diffuse optical spectroscopy with magnetic resonance imaging coregistration,” Appl. Opt. 42(16), 2940–2950 (2003).
[PubMed]
G. Brix, F. Kiessling, R. Lucht, S. Darai, K. Wasser, S. Delorme, and J. Griebel, “Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series,” Magn. Reson. Med. 52(2), 420–429 (2004).
[PubMed]
E. E. Uzgiris, “Tumor microvasculature: endothelial leakiness and endothelial pore size distribution in a breast cancer model,” Breast Cancer: Basic and Clinical Research 1, 83–90 (2008).
H. Daldrup, D. M. Shames, M. Wendland, Y. Okuhata, T. M. Link, W. Rosenau, Y. Lu, and R. C. Brasch, “Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media,” AJR Am. J. Roentgenol. 171(4), 941–949 (1998).
[PubMed]
C. C. Michel and F. E. Curry, “Microvascular permeability,” Physiol. Rev. 79(3), 703–761 (1999).
[PubMed]
M. R. Dreher, W. Liu, C. R. Michelich, M. W. Dewhirst, F. Yuan, and A. Chilkoti, “Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers,” J. Natl. Cancer Inst. 98(5), 335–344 (2006).
[PubMed]
H. E. Daldrup-Link and R. C. Brasch, “Macromolecular contrast agents for MR mammography: current status,” Eur. Radiol. 13(2), 354–365 (2003).
[PubMed]
P. Ott and R. A. Weisiger, “Nontraditional effects of protein binding and hematocrit on uptake of indocyanine green by perfused rat liver,” Am. J. Physiol. 273(1 Pt 1), G227–G238 (1997).
[PubMed]
S. Keiding, P. Ott, and L. Bass, “Enhancement of unbound clearance of ICG by plasma proteins, demonstrated in human subjects and interpreted without assumption of facilitating structures,” J. Hepatol. 19(3), 327–344 (1993).
[PubMed]
K. Sauda, T. Imasaka, and N. Ishibashi, “Determination of protein in human serum by high-performance liquid chromatography with semiconductor laser fluorometric detection,” Anal. Chem. 58(13), 2649–2653 (1986).
[PubMed]
S. Yoneya, T. Saito, Y. Komatsu, I. Koyama, K. Takahashi, and J. Duvoll-Young, “Binding properties of indocyanine green in human blood,” Invest. Ophthalmol. Vis. Sci. 39(7), 1286–1290 (1998).
[PubMed]
Z. M. Bhujwalla, D. Artemov, K. Natarajan, E. Ackerstaff, and M. Solaiyappan, “Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts,” Neoplasia 3(2), 143–153 (2001).
[PubMed]
B. Alacam, B. Yazici, X. Intes, S. Nioka, and B. Chance, “Pharmacokinetic-rate images of indocyanine green for breast tumors using near-infrared optical methods,” Phys. Med. Biol. 53(4), 837–859 (2008).
[PubMed]
Y. Matsumura and H. Maeda, “A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs,” Cancer Res. 46(12 Pt 1), 6387–6392 (1986).
[PubMed]
U. Schilling, E. A. Friedrich, H. Sinn, H. H. Schrenk, J. H. Clorius, and W. Maier-Borst, “Design of compounds having enhanced tumor uptake, using serum albumin as a carrier – Part II. In vivo studies,” Nucl. Med. Biol. 19(6), 685–695 (1992).
R. Duncan, “Polymer conjugates as anticancer nanomedicines,” Nat. Rev. Cancer 6(9), 688–701 (2006).
[PubMed]
M. Gurfinkel, A. B. Thompson, W. Ralston, T. L. Troy, A. L. Moore, T. A. Moore, J. D. Gust, D. Tatman, J. S. Reynolds, B. Muggenburg, K. Nikula, R. Pandey, R. H. Mayer, D. J. Hawrysz, and E. M. Sevick-Muraca, “Pharmacokinetics of ICG and HPPH-car for the detection of normal and tumor tissue using fluorescence, near-infrared reflectance imaging: a case study,” Photochem. Photobiol. 72(1), 94–102 (2000).
[PubMed]
E. Brown, J. Hopper, J. L. Hodges, B. Bradley, R. Wennesland, and H. Yamauchi, “Red cell, plasma, and blood volume in the healthy women measured by radiochromium cell-labeling and hematocrit,” J. Clin. Invest. 41(12), 2182–2190 (1962).
[PubMed]
C. B. Wilson, A. A. Lammertsma, C. G. McKenzie, K. Sikora, and T. Jones, “Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method,” Cancer Res. 52(6), 1592–1597 (1992).
[PubMed]
P. Vaupel and M. Höckel, “Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance,” Int. J. Oncol. 17(5), 869–879 (2000) (review).
[PubMed]
D. Grosenick, H. Wabnitz, K. Th. Moesta, J. Mucke, P. M. Schlag, and H. Rinneberg, “Time-domain scanning optical mammography: II. Optical properties and tissue parameters of 87 carcinomas,” Phys. Med. Biol. 50(11), 2451–2468 (2005).
[PubMed]
P. S. Tofts and B. A. Berkowitz, “Measurement of capillary permeability from the Gd enhancement curve: a comparison of bolus and constant infusion injection methods,” Magn. Reson. Imaging 12(1), 81–91 (1994).
[PubMed]

2008 (4)

H. Rinneberg, D. Grosenick, K. T. Moesta, H. Wabnitz, J. Mucke, G. Wübbeler, R. Macdonald, and P. Schlag, “Detection and characterization of breast tumours by time-domain scanning optical mammography,” Opto-Electronics Review 16(2), 147–162 (2008).

S. A. Carp, J. Selb, Q. Fang, R. Moore, D. B. Kopans, E. Rafferty, and D. A. Boas, “Dynamic functional and mechanical response of breast tissue to compression,” Opt. Express 16(20), 16064–16078 (2008).
[PubMed]

E. E. Uzgiris, “Tumor microvasculature: endothelial leakiness and endothelial pore size distribution in a breast cancer model,” Breast Cancer: Basic and Clinical Research 1, 83–90 (2008).

B. Alacam, B. Yazici, X. Intes, S. Nioka, and B. Chance, “Pharmacokinetic-rate images of indocyanine green for breast tumors using near-infrared optical methods,” Phys. Med. Biol. 53(4), 837–859 (2008).
[PubMed]

2007 (5)

A. Hagen, O. Steinkellner, D. Grosenick, M. Möller, R. Ziegler, T. Nielsen, K. Lauritsen, R. Macdonald, and H. Rinneberg, “Development of a multi-channel time-domain fluorescence mammograph,” Proc. SPIE 6434, 64340Z (2007).

S. P. Poplack, T. D. Tosteson, W. A. Wells, B. W. Pogue, P. M. Meaney, A. Hartov, C. A. Kogel, S. K. Soho, J. J. Gibson, and K. D. Paulsen, “Electromagnetic breast imaging: results of a pilot study in women with abnormal mammograms,” Radiology 243(2), 350–359 (2007).
[PubMed]

A. Corlu, R. Choe, T. Durduran, M. A. Rosen, M. Schweiger, S. R. Arridge, M. D. Schnall, and A. G. Yodh, “Three-dimensional in vivo fluorescence diffuse optical tomography of breast cancer in humans,” Opt. Express 15(11), 6696–6716 (2007).
[PubMed]

A. Cerussi, D. Hsiang, N. Shah, R. Mehta, A. Durkin, J. Butler, and B. J. Tromberg, “Predicting response to breast cancer neoadjuvant chemotherapy using diffuse optical spectroscopy,” Proc. Natl. Acad. Sci. U.S.A. 104(10), 4014–4019 (2007).
[PubMed]

C. Zhou, R. Choe, N. Shah, T. Durduran, G. Yu, A. Durkin, D. Hsiang, R. Mehta, J. Butler, A. Cerussi, B. J. Tromberg, and A. G. Yodh, “Diffuse optical monitoring of blood flow and oxygenation in human breast cancer during early stages of neoadjuvant chemotherapy,” J. Biomed. Opt. 12(5), 051903 (2007).
[PubMed]

2006 (4)

A. Cerussi, N. Shah, D. Hsiang, A. Durkin, J. Butler, and B. J. Tromberg, “In vivo absorption, scattering, and physiologic properties of 58 malignant breast tumors determined by broadband diffuse optical spectroscopy,” J. Biomed. Opt. 11(4), 044005 (2006).
[PubMed]

B. W. Pogue, S. C. Davis, X. Song, B. A. Brooksby, H. Dehghani, and K. D. Paulsen, “Image analysis methods for diffuse optical tomography,” J. Biomed. Opt. 11(3), 033001 (2006).

M. R. Dreher, W. Liu, C. R. Michelich, M. W. Dewhirst, F. Yuan, and A. Chilkoti, “Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers,” J. Natl. Cancer Inst. 98(5), 335–344 (2006).
[PubMed]

R. Duncan, “Polymer conjugates as anticancer nanomedicines,” Nat. Rev. Cancer 6(9), 688–701 (2006).
[PubMed]

2005 (4)

D. Grosenick, H. Wabnitz, K. Th. Moesta, J. Mucke, P. M. Schlag, and H. Rinneberg, “Time-domain scanning optical mammography: II. Optical properties and tissue parameters of 87 carcinomas,” Phys. Med. Biol. 50(11), 2451–2468 (2005).
[PubMed]

C. Perlitz, K. Licha, F. D. Scholle, B. Ebert, M. Bahner, P. Hauff, K. T. Moesta, and M. Schirner, “Comparison of two tricarbocyanine-based dyes for fluorescence optical imaging,” J. Fluoresc. 15(3), 443–454 (2005).
[PubMed]

P. Taroni, A. Torricelli, L. Spinelli, A. Pifferi, F. Arpaia, G. Danesini, and R. Cubeddu, “Time-resolved optical mammography between 637 and 985 nm: clinical study on the detection and identification of breast lesions,” Phys. Med. Biol. 50(11), 2469–2488 (2005).
[PubMed]

D. Grosenick, K. Th. Moesta, M. Möller, J. Mucke, H. Wabnitz, B. Gebauer, Ch. Stroszczynski, B. Wassermann, P. M. Schlag, and H. Rinneberg, “Time-domain scanning optical mammography: I. Recording and assessment of mammograms of 154 patients,” Phys. Med. Biol. 50(11), 2429–2449 (2005).
[PubMed]

2004 (1)

G. Brix, F. Kiessling, R. Lucht, S. Darai, K. Wasser, S. Delorme, and J. Griebel, “Microcirculation and microvasculature in breast tumors: pharmacokinetic analysis of dynamic MR image series,” Magn. Reson. Med. 52(2), 420–429 (2004).
[PubMed]

2003 (5)

M. Möller, H. Wabnitz, A. Kummrow, D. Grosenick, A. Liebert, B. Wassermann, R. Macdonald, and H. Rinneberg, “A four-wavelength multi-channel scanning time-resolved optical mammograph,” Proc. SPIE 5138, 290–297 (2003).

D. J. Cuccia, F. Bevilacqua, A. J. Durkin, S. Merritt, B. J. Tromberg, G. Gulsen, H. Yu, J. Wang, and O. Nalcioglu, “In vivo quantification of optical contrast agent dynamics in rat tumors by use of diffuse optical spectroscopy with magnetic resonance imaging coregistration,” Appl. Opt. 42(16), 2940–2950 (2003).
[PubMed]

H. E. Daldrup-Link and R. C. Brasch, “Macromolecular contrast agents for MR mammography: current status,” Eur. Radiol. 13(2), 354–365 (2003).
[PubMed]

H. Dehghani, B. W. Pogue, S. P. Poplack, and K. D. Paulsen, “Multiwavelength three-dimensional near-infrared tomography of the breast: initial simulation, phantom, and clinical results,” Appl. Opt. 42(1), 135–145 (2003).
[PubMed]

X. Intes, J. Ripoll, Y. Chen, S. Nioka, A. G. Yodh, and B. Chance, “In vivo continuous-wave optical breast imaging enhanced with Indocyanine Green,” Med. Phys. 30(6), 1039–1047 (2003).
[PubMed]

2002 (1)

D. Feng, J. A. Nagy, H. F. Dvorak, and A. M. Dvorak, “Ultrastructural studies define soluble macromolecular, particulate, and cellular transendothelial cell pathways in venules, lymphatic vessels, and tumor-associated microvessels in man and animals,” Microsc. Res. Tech. 57(5), 289–326 (2002).
[PubMed]

2001 (1)

Z. M. Bhujwalla, D. Artemov, K. Natarajan, E. Ackerstaff, and M. Solaiyappan, “Vascular differences detected by MRI for metastatic versus nonmetastatic breast and prostate cancer xenografts,” Neoplasia 3(2), 143–153 (2001).
[PubMed]

2000 (5)

M. Gurfinkel, A. B. Thompson, W. Ralston, T. L. Troy, A. L. Moore, T. A. Moore, J. D. Gust, D. Tatman, J. S. Reynolds, B. Muggenburg, K. Nikula, R. Pandey, R. H. Mayer, D. J. Hawrysz, and E. M. Sevick-Muraca, “Pharmacokinetics of ICG and HPPH-car for the detection of normal and tumor tissue using fluorescence, near-infrared reflectance imaging: a case study,” Photochem. Photobiol. 72(1), 94–102 (2000).
[PubMed]

P. Vaupel and M. Höckel, “Blood supply, oxygenation status and metabolic micromilieu of breast cancers: characterization and therapeutic relevance,” Int. J. Oncol. 17(5), 869–879 (2000) (review).
[PubMed]

P. Carmeliet and R. K. Jain, “Angiogenesis in cancer and other diseases,” Nature 407(6801), 249–257 (2000).
[PubMed]

H. Hashizume, P. Baluk, S. Morikawa, J. W. McLean, G. Thurston, S. Roberge, R. K. Jain, and D. M. McDonald, “Openings between defective endothelial cells explain tumor vessel leakiness,” Am. J. Pathol. 156(4), 1363–1380 (2000).
[PubMed]

V. Ntziachristos, A. G. Yodh, M. Schnall, and B. Chance, “Concurrent MRI and diffuse optical tomography of breast after indocyanine green enhancement,” Proc. Natl. Acad. Sci. U.S.A. 97(6), 2767–2772 (2000).
[PubMed]

1999 (3)

S. B. Colak, M. B. van der Mark, G. W. 't Hooft, J. H. Hoogenraad, E. S. van der Linden, and F. A. Kuijpers, “Clinical optical tomography and NIR spectroscopy for breast cancer detection,” IEEE J. Sel. Top. Quantum Electron. 5(4), 1143–1158 (1999).

D. Grosenick, H. Wabnitz, H. H. Rinneberg, K. Th. Moesta, and P. M. Schlag, “Development of a time-domain optical mammograph and first in vivo applications,” Appl. Opt. 38(13), 2927–2943 (1999).

C. C. Michel and F. E. Curry, “Microvascular permeability,” Physiol. Rev. 79(3), 703–761 (1999).
[PubMed]

1998 (3)

S. Yoneya, T. Saito, Y. Komatsu, I. Koyama, K. Takahashi, and J. Duvoll-Young, “Binding properties of indocyanine green in human blood,” Invest. Ophthalmol. Vis. Sci. 39(7), 1286–1290 (1998).
[PubMed]

H. Daldrup, D. M. Shames, M. Wendland, Y. Okuhata, T. M. Link, W. Rosenau, Y. Lu, and R. C. Brasch, “Correlation of dynamic contrast-enhanced MR imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media,” AJR Am. J. Roentgenol. 171(4), 941–949 (1998).
[PubMed]

L. Götz, S. H. Heywang-Köbrunner, O. Schütz, and H. Siebold, “Optical mammography on preoperative patients (Optische Mammographie an präoperativen Patientinnen),” Akt. Radiol. 8, 31–33 (1998).

1997 (2)

M. A. Franceschini, K. T. Moesta, S. Fantini, G. Gaida, E. Gratton, H. Jess, W. W. Mantulin, M. Seeber, P. M. Schlag, and M. Kaschke, “Frequency-domain techniques enhance optical mammography: initial clinical results,” Proc. Natl. Acad. Sci. U.S.A. 94(12), 6468–6473 (1997).
[PubMed]

P. Ott and R. A. Weisiger, “Nontraditional effects of protein binding and hematocrit on uptake of indocyanine green by perfused rat liver,” Am. J. Physiol. 273(1 Pt 1), G227–G238 (1997).
[PubMed]

1996 (1)

P. Ott, L. Bass, and S. Keiding, “The kinetics of continuously infused indocyanine green in the pig,” J. Pharmacokinet. Biopharm. 24(1), 19–44 (1996).
[PubMed]

1994 (1)

P. S. Tofts and B. A. Berkowitz, “Measurement of capillary permeability from the Gd enhancement curve: a comparison of bolus and constant infusion injection methods,” Magn. Reson. Imaging 12(1), 81–91 (1994).
[PubMed]

1993 (1)

S. Keiding, P. Ott, and L. Bass, “Enhancement of unbound clearance of ICG by plasma proteins, demonstrated in human subjects and interpreted without assumption of facilitating structures,” J. Hepatol. 19(3), 327–344 (1993).
[PubMed]

1992 (2)

C. B. Wilson, A. A. Lammertsma, C. G. McKenzie, K. Sikora, and T. Jones, “Measurements of blood flow and exchanging water space in breast tumors using positron emission tomography: a rapid and noninvasive dynamic method,” Cancer Res. 52(6), 1592–1597 (1992).
[PubMed]

U. Schilling, E. A. Friedrich, H. Sinn, H. H. Schrenk, J. H. Clorius, and W. Maier-Borst, “Design of compounds having enhanced tumor uptake, using serum albumin as a carrier – Part II. In vivo studies,” Nucl. Med. Biol. 19(6), 685–695 (1992).

1988 (1)

D. K. F. Meijer, B. Weert, and G. A. Vermeer, “Pharmacokinetics of biliary excretion in man. VI. Indocyanine green,” Eur. J. Clin. Pharmacol. 35(3), 295–303 (1988).
[PubMed]

1986 (2)

K. Sauda, T. Imasaka, and N. Ishibashi, “Determination of protein in human serum by high-performance liquid chromatography with semiconductor laser fluorometric detection,” Anal. Chem. 58(13), 2649–2653 (1986).
[PubMed]

Y. Matsumura and H. Maeda, “A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs,” Cancer Res. 46(12 Pt 1), 6387–6392 (1986).
[PubMed]

1962 (1)

E. Brown, J. Hopper, J. L. Hodges, B. Bradley, R. Wennesland, and H. Yamauchi, “Red cell, plasma, and blood volume in the healthy women measured by radiochromium cell-labeling and hematocrit,” J. Clin. Invest. 41(12), 2182–2190 (1962).
[PubMed]

Ackerstaff, E.

Alacam, B.

Arpaia, F.

Arridge, S. R.

Artemov, D.

Bahner, M.

Baluk, P.

Bass, L.

P. Ott, L. Bass, and S. Keiding, “The kinetics of continuously infused indocyanine green in the pig,” J. Pharmacokinet. Biopharm. 24(1), 19–44 (1996).
[PubMed]

Berkowitz, B. A.

Bevilacqua, F.

Bhujwalla, Z. M.

Boas, D. A.

Bradley, B.

Brasch, R. C.

H. E. Daldrup-Link and R. C. Brasch, “Macromolecular contrast agents for MR mammography: current status,” Eur. Radiol. 13(2), 354–365 (2003).
[PubMed]

Brix, G.

Brooksby, B. A.

B. W. Pogue, S. C. Davis, X. Song, B. A. Brooksby, H. Dehghani, and K. D. Paulsen, “Image analysis methods for diffuse optical tomography,” J. Biomed. Opt. 11(3), 033001 (2006).

Brown, E.

Butler, J.

Carmeliet, P.

P. Carmeliet and R. K. Jain, “Angiogenesis in cancer and other diseases,” Nature 407(6801), 249–257 (2000).
[PubMed]

Carp, S. A.

Cerussi, A.

Chance, B.

X. Intes, J. Ripoll, Y. Chen, S. Nioka, A. G. Yodh, and B. Chance, “In vivo continuous-wave optical breast imaging enhanced with Indocyanine Green,” Med. Phys. 30(6), 1039–1047 (2003).
[PubMed]

Chen, Y.

X. Intes, J. Ripoll, Y. Chen, S. Nioka, A. G. Yodh, and B. Chance, “In vivo continuous-wave optical breast imaging enhanced with Indocyanine Green,” Med. Phys. 30(6), 1039–1047 (2003).
[PubMed]

Chilkoti, A.

Choe, R.

Clorius, J. H.

Colak, S. B.

Corlu, A.

Cubeddu, R.

Cuccia, D. J.

Curry, F. E.

C. C. Michel and F. E. Curry, “Microvascular permeability,” Physiol. Rev. 79(3), 703–761 (1999).
[PubMed]

Daldrup, H.

Daldrup-Link, H. E.

H. E. Daldrup-Link and R. C. Brasch, “Macromolecular contrast agents for MR mammography: current status,” Eur. Radiol. 13(2), 354–365 (2003).
[PubMed]

Danesini, G.

Darai, S.

Davis, S. C.

B. W. Pogue, S. C. Davis, X. Song, B. A. Brooksby, H. Dehghani, and K. D. Paulsen, “Image analysis methods for diffuse optical tomography,” J. Biomed. Opt. 11(3), 033001 (2006).

Dehghani, H.

B. W. Pogue, S. C. Davis, X. Song, B. A. Brooksby, H. Dehghani, and K. D. Paulsen, “Image analysis methods for diffuse optical tomography,” J. Biomed. Opt. 11(3), 033001 (2006).

Delorme, S.

Dewhirst, M. W.

Dreher, M. R.

Duncan, R.

R. Duncan, “Polymer conjugates as anticancer nanomedicines,” Nat. Rev. Cancer 6(9), 688–701 (2006).
[PubMed]

Durduran, T.

Durkin, A.

Durkin, A. J.

Duvoll-Young, J.

Dvorak, A. M.

Dvorak, H. F.

Ebert, B.

Fang, Q.

Fantini, S.

Feng, D.

Franceschini, M. A.

Friedrich, E. A.

Gaida, G.

Gebauer, B.

Gibson, J. J.

Götz, L.

Gratton, E.

Griebel, J.

Grosenick, D.

Gulsen, G.

Gurfinkel, M.

Gust, J. D.

Hagen, A.

Hartov, A.

Hashizume, H.

Hauff, P.

Hawrysz, D. J.

Heywang-Köbrunner, S. H.

Höckel, M.

Hodges, J. L.

Hoogenraad, J. H.

Hopper, J.

Hsiang, D.

Imasaka, T.

Intes, X.

X. Intes, J. Ripoll, Y. Chen, S. Nioka, A. G. Yodh, and B. Chance, “In vivo continuous-wave optical breast imaging enhanced with Indocyanine Green,” Med. Phys. 30(6), 1039–1047 (2003).
[PubMed]

Ishibashi, N.

Jain, R. K.

P. Carmeliet and R. K. Jain, “Angiogenesis in cancer and other diseases,” Nature 407(6801), 249–257 (2000).
[PubMed]

Jess, H.

Jones, T.

Kaschke, M.

Keiding, S.

P. Ott, L. Bass, and S. Keiding, “The kinetics of continuously infused indocyanine green in the pig,” J. Pharmacokinet. Biopharm. 24(1), 19–44 (1996).
[PubMed]

Kiessling, F.

Kogel, C. A.

Komatsu, Y.

Kopans, D. B.

Koyama, I.

Kuijpers, F. A.

Kummrow, A.

Lammertsma, A. A.

Lauritsen, K.

Licha, K.

Liebert, A.

Link, T. M.

Liu, W.

Lu, Y.

Lucht, R.

Macdonald, R.

Maeda, H.

Maier-Borst, W.

Mantulin, W. W.

Matsumura, Y.

Mayer, R. H.

McDonald, D. M.

McKenzie, C. G.

McLean, J. W.

Meaney, P. M.

Mehta, R.

Meijer, D. K. F.

D. K. F. Meijer, B. Weert, and G. A. Vermeer, “Pharmacokinetics of biliary excretion in man. VI. Indocyanine green,” Eur. J. Clin. Pharmacol. 35(3), 295–303 (1988).
[PubMed]

Merritt, S.

Michel, C. C.

C. C. Michel and F. E. Curry, “Microvascular permeability,” Physiol. Rev. 79(3), 703–761 (1999).
[PubMed]

Michelich, C. R.

Moesta, K. T.

Moesta, K. Th.

Möller, M.

Moore, A. L.

Moore, R.

Moore, T. A.

Morikawa, S.

Mucke, J.

Muggenburg, B.

Nagy, J. A.

Nalcioglu, O.

Natarajan, K.

Nielsen, T.

Nikula, K.

Nioka, S.

X. Intes, J. Ripoll, Y. Chen, S. Nioka, A. G. Yodh, and B. Chance, “In vivo continuous-wave optical breast imaging enhanced with Indocyanine Green,” Med. Phys. 30(6), 1039–1047 (2003).
[PubMed]

Ntziachristos, V.

Okuhata, Y.

Ott, P.

P. Ott, L. Bass, and S. Keiding, “The kinetics of continuously infused indocyanine green in the pig,” J. Pharmacokinet. Biopharm. 24(1), 19–44 (1996).
[PubMed]

Pandey, R.

Paulsen, K. D.

B. W. Pogue, S. C. Davis, X. Song, B. A. Brooksby, H. Dehghani, and K. D. Paulsen, “Image analysis methods for diffuse optical tomography,” J. Biomed. Opt. 11(3), 033001 (2006).

Perlitz, C.

Pifferi, A.

Pogue, B. W.

B. W. Pogue, S. C. Davis, X. Song, B. A. Brooksby, H. Dehghani, and K. D. Paulsen, “Image analysis methods for diffuse optical tomography,” J. Biomed. Opt. 11(3), 033001 (2006).

Poplack, S. P.

Rafferty, E.

Ralston, W.

Reynolds, J. S.

Rinneberg, H.

Rinneberg, H. H.

Ripoll, J.

X. Intes, J. Ripoll, Y. Chen, S. Nioka, A. G. Yodh, and B. Chance, “In vivo continuous-wave optical breast imaging enhanced with Indocyanine Green,” Med. Phys. 30(6), 1039–1047 (2003).
[PubMed]

Roberge, S.

Rosen, M. A.

Rosenau, W.

Saito, T.

Sauda, K.

Schilling, U.

Schirner, M.

Schlag, P.

Schlag, P. M.

Schnall, M.

Schnall, M. D.

Scholle, F. D.

Schrenk, H. H.

Schütz, O.

Schweiger, M.

Seeber, M.

Selb, J.

Sevick-Muraca, E. M.

Shah, N.

Shames, D. M.

Siebold, H.

Sikora, K.

Sinn, H.

Soho, S. K.

Solaiyappan, M.

Song, X.

B. W. Pogue, S. C. Davis, X. Song, B. A. Brooksby, H. Dehghani, and K. D. Paulsen, “Image analysis methods for diffuse optical tomography,” J. Biomed. Opt. 11(3), 033001 (2006).

Spinelli, L.

Steinkellner, O.

Stroszczynski, Ch.

't Hooft, G. W.

Takahashi, K.

Taroni, P.

Tatman, D.

Thompson, A. B.

Thurston, G.

Tofts, P. S.

Torricelli, A.

Tosteson, T. D.

Tromberg, B. J.

Troy, T. L.

Uzgiris, E. E.

E. E. Uzgiris, “Tumor microvasculature: endothelial leakiness and endothelial pore size distribution in a breast cancer model,” Breast Cancer: Basic and Clinical Research 1, 83–90 (2008).

van der Linden, E. S.

van der Mark, M. B.

Vaupel, P.

Vermeer, G. A.

D. K. F. Meijer, B. Weert, and G. A. Vermeer, “Pharmacokinetics of biliary excretion in man. VI. Indocyanine green,” Eur. J. Clin. Pharmacol. 35(3), 295–303 (1988).
[PubMed]

Wabnitz, H.

Wang, J.

Wasser, K.

Wassermann, B.

Weert, B.

D. K. F. Meijer, B. Weert, and G. A. Vermeer, “Pharmacokinetics of biliary excretion in man. VI. Indocyanine green,” Eur. J. Clin. Pharmacol. 35(3), 295–303 (1988).
[PubMed]

Weisiger, R. A.

Wells, W. A.

Wendland, M.

Wennesland, R.

Wilson, C. B.

Wübbeler, G.

Yamauchi, H.

Yazici, B.

Yodh, A. G.

X. Intes, J. Ripoll, Y. Chen, S. Nioka, A. G. Yodh, and B. Chance, “In vivo continuous-wave optical breast imaging enhanced with Indocyanine Green,” Med. Phys. 30(6), 1039–1047 (2003).
[PubMed]

Yoneya, S.

Yu, G.

Yu, H.

Yuan, F.

Zhou, C.

Ziegler, R.

AJR Am. J. Roentgenol. (1)

Akt. Radiol. (1)

Am. J. Pathol. (1)

Am. J. Physiol. (1)

Anal. Chem. (1)

Appl. Opt. (3)

Breast Cancer: Basic and Clinical Research (1)

E. E. Uzgiris, “Tumor microvasculature: endothelial leakiness and endothelial pore size distribution in a breast cancer model,” Breast Cancer: Basic and Clinical Research 1, 83–90 (2008).

Cancer Res. (2)

Eur. J. Clin. Pharmacol. (1)

D. K. F. Meijer, B. Weert, and G. A. Vermeer, “Pharmacokinetics of biliary excretion in man. VI. Indocyanine green,” Eur. J. Clin. Pharmacol. 35(3), 295–303 (1988).
[PubMed]

Eur. Radiol. (1)

H. E. Daldrup-Link and R. C. Brasch, “Macromolecular contrast agents for MR mammography: current status,” Eur. Radiol. 13(2), 354–365 (2003).
[PubMed]

IEEE J. Sel. Top. Quantum Electron. (1)

Int. J. Oncol. (1)

Invest. Ophthalmol. Vis. Sci. (1)

J. Biomed. Opt. (3)

B. W. Pogue, S. C. Davis, X. Song, B. A. Brooksby, H. Dehghani, and K. D. Paulsen, “Image analysis methods for diffuse optical tomography,” J. Biomed. Opt. 11(3), 033001 (2006).

J. Clin. Invest. (1)

J. Fluoresc. (1)

J. Hepatol. (1)

J. Natl. Cancer Inst. (1)

J. Pharmacokinet. Biopharm. (1)

P. Ott, L. Bass, and S. Keiding, “The kinetics of continuously infused indocyanine green in the pig,” J. Pharmacokinet. Biopharm. 24(1), 19–44 (1996).
[PubMed]

Magn. Reson. Imaging (1)

Magn. Reson. Med. (1)

Med. Phys. (1)

X. Intes, J. Ripoll, Y. Chen, S. Nioka, A. G. Yodh, and B. Chance, “In vivo continuous-wave optical breast imaging enhanced with Indocyanine Green,” Med. Phys. 30(6), 1039–1047 (2003).
[PubMed]

Microsc. Res. Tech. (1)

Nat. Rev. Cancer (1)

R. Duncan, “Polymer conjugates as anticancer nanomedicines,” Nat. Rev. Cancer 6(9), 688–701 (2006).
[PubMed]

Nature (1)

P. Carmeliet and R. K. Jain, “Angiogenesis in cancer and other diseases,” Nature 407(6801), 249–257 (2000).
[PubMed]

Neoplasia (1)

Nucl. Med. Biol. (1)

Opt. Express (2)

Opto-Electronics Review (1)

Photochem. Photobiol. (1)

Phys. Med. Biol. (4)

Physiol. Rev. (1)

C. C. Michel and F. E. Curry, “Microvascular permeability,” Physiol. Rev. 79(3), 703–761 (1999).
[PubMed]

Proc. Natl. Acad. Sci. U.S.A. (3)

Proc. SPIE (2)

Radiology (1)

Other (2)

R. Ziegler, Modeling photon transport and reconstruction of optical properties for performance assessment of laser und fluorescence mammographs and analysis of clinical data, Dissertation, Department of Physics, Free University of Berlin, Germany, 2008, ( http://www.diss.fu-berlin.de/diss/receive/FUDISS_thesis_000000005928 ).

A. L. Baert, K. Sartor, A. Jackson, D. L. Buckley, and G. J. M. Parker, eds., Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Oncology, Springer, Berlin, Heidelberg, Germany (2005).

Cited By

OSA participates in Crossref's Cited-By Linking service. Citing articles from OSA journals and other participating publishers are listed here.

Alert me when this article is cited.

Click here to see a list of articles that cite this paper

Fig. 1

Time course of molar ICG concentration in plasma of arterial blood, recorded at the finger pad of a 72-year-old patient by transcutaneous pulse densitometry. The entire time course is divided into five periods corresponding to the initial (native) phase, the period during which the ICG bolus is administered (bolus phase), the infusion period (vascular phase), the washout phase after termination of the infusion and the extravascular phase when the ICG arterial plasma concentration has returned to zero. Periods during which absorption and fluorescence mammograms were taken are indicated by vertical bars. The red solid line represents a mono-exponential fit of the ICG decay after the infusion was stopped.

Download Full Size | PPT Slide | PDF

Fig. 2

Schematic of scanning time-domain laser and fluorescence mammograph.

Download Full Size | PPT Slide | PDF

Fig. 3

Fluorescence raw mammogram (a) based on diffusely transmitted, time-integrated fluorescence intensity, absorption raw mammogram (b), corresponding to time-integrated transmitted laser intensity and corresponding ratio mammogram of (a) and (b) without edge correction (c) and with edge correction (d). Unlike ratio images, absorption and fluorescence mammograms are dominated by hemoglobin absorption. The carcinoma (arrow) is visible in laser and ratio mammograms but invisible in the fluorescence mammogram due to cancellation effects. Each mammogram is normalized to the center region of the breast.

Download Full Size | PPT Slide | PDF

Fig. 4

Open unidirectional compartmental model (right hand side, solid lines) for simulating local ICG concentrations. Model consists of local vascular (plasma) compartment and local extravascular-extracellular space (EES), with apparent capillary plasma flow per unit volume of tissue (F_pρ), apparent permeability-surface-area product (PSρ) and (bound) ICG outflow rate (k_out) entering as parameters (s. Table 1). Left hand side (dashed lines) illustrates (global) open redistribution compartment model used by Ott et al. [23] to interpret ICG plasma disappearance curve.

Download Full Size | PPT Slide | PDF

Fig. 5

Fluorescence ratio images taken (a) in the vascular phase, i.e. during ICG infusion (Scan 3, s. Figure 1), and (b) in the extravascular phase, i.e. about 30 min post infusion (Scan 5, Fig. 1), of 72-year-old patient; (c) x-ray mammogram shown for comparison with arrow indicating the position of the invasive ductal carcinoma. In (a) fluorescence originates predominantly from ICG in vasculature, in (b) fluorescence predominantly reflects ICG that extravasated into the interstitium. The higher fluorescence intensity of the carcinoma reveals its higher permeability for ICG bound plasma proteins. Distance between image-ticks is 2 cm.

Download Full Size | PPT Slide | PDF

Fig. 6

Mammogram showing reciprocal photon counts of a late time window of the TPSF recorded at 660 nm prior to ICG administration (a). The intrinsic absorption contrast reveals structures that can also be seen in the fluorescence ratio image taken during the vascular phase (b). Distance between image-ticks is 2 cm.

Download Full Size | PPT Slide | PDF

Fig. 7

X-ray-mammogram (cranio-caudal projection) of the left breast of a 51-year-old patient bearing an invasive ductal carcinoma. The tumor is hardly visible due to very dense glandular tissue.

Download Full Size | PPT Slide | PDF

Fig. 8

Fluorescence ratio images in cranio-caudal projection taken (a) in the vascular phase and (b) in the extravascular phase 54 min after termination of ICG infusion. Axial reconstruction of Gd-DTPA enhanced MR breast scan (c) showing maximum intensity projection. In contrast to x-ray mammogram (s. Figure 7), late-fluorescence ratio mammogram (b) and MR image reveal the ductal carcinoma indicated by arrows in (c). Distance between image-ticks is 2 cm.

Download Full Size | PPT Slide | PDF

Fig. 9

Fluorescence ratio mammograms in cranio-caudal projection taken (a) in the vascular phase and (b) in the extravascular phase, 26 min after termination of ICG infusion, of a 52-year-old patient with benign fibroadenoma. The lesion does not lead to a focused area with higher fluorescence intensity above background, i.e. is invisible in the ratio images, indicating that ICG extravasated at a rate comparable with normal breast tissue. Distance between image-ticks is 2 cm.

Download Full Size | PPT Slide | PDF

Fig. 10

(a,b) Simulated time course of concentration corresponding to (a) vascular contribution (v_pC_p(t)), and (b) extravascular contribution (v_eC_e(t)) to total ICG concentration in carcinoma (), breast parenchyma () and normal breast tissue (fat) () during (0 ≤ t ≤ 25 min) and after ICG infusion, with simulation input parameters listed in Table 1; (c,d) Simulated concentration contrast of (c) intravascular (v_pC_p(t)) and extravascular (v_eC_e(t)) contributions and (d) of total ICG concentration normalized to total ICG concentration C_t in normal breast tissue (fat) for carcinoma (), breast parenchyma () and fat (). In (c,d) vertical gray bars indicate periods during which optical mammograms of the 72-year-old patient were recorded (case 1, Scan 3, Scan 5, s. Figure 1).

Download Full Size | PPT Slide | PDF

Tables (2)

Table 1 Simulation input parameters

View Table | View all tables in this article

Table A1 Coefficients and abbreviations used in analytical solutions of rate equations

View Table | View all tables in this article

Equations (9)

Equations on this page are rendered with MathJax. Learn more.

\frac{d C_{A}^{s s}}{d t} = - k_{e l i m} C_{A}^{s s} + S_{i n f} = 0

d C_{p} (t) / d t = k_{F} C_{A} (t) - (k_{F} + k_{p}^{P S ρ}) C_{p} (t)

d C_{e} (t) / d t = k_{e}^{P S ρ} C_{p} (t) - k_{o u t} C_{e} (t)

C_{A}^{b o l u s} (t) = A_{1} \exp (- m_{1} t) + A_{2} \exp (- m_{2} t)

C_{A} (t) = \frac{S_{i n f}}{k_{e l i m}} {1 - q \exp (- m_{1} t) - (1 - q) \exp (- m_{2} t)}

C_{p} (t) = A_{0} - A_{m 1}^{(1)} \exp (- m_{1} t) - A_{m 2}^{(1)} \exp (- m_{2} t) + A_{F}^{(1)} \exp {- (k_{F} + k_{p}^{P S ρ}) t}

\begin{array}{c} C_{e} (t) = B_{0} + B_{m 1}^{(1)} \exp (- m_{1} t) + B_{m 2}^{(1)} \exp (- m_{2} t) \\ - f_{o u t} A_{F}^{(1)} \exp {- (k_{F} + k_{p}^{P S ρ}) t} - B_{o u t}^{(1)} \exp {- k_{o u t} t} \end{array}

\begin{array}{c} C_{p} (t) = A_{m 1}^{(2)} \exp {- m_{1} (t - τ_{i n f})} + A_{m 2}^{(2)} \exp {- m_{2} (t - τ_{i n f})} \\ - A_{F}^{(2)} \exp {- (k_{F} + k_{p}^{P S ρ}) (t - τ_{i n f})} \end{array}

\begin{array}{l} C_{e} (t) = - B_{m 1}^{(2)} \exp {- m_{1} (t - τ_{i n f})} - B_{m 2}^{(2)} \exp {- m_{2} (t - τ_{i n f})} \\ + f_{o u t} A_{F}^{(2)} \exp {- (k_{F} + k_{p}^{P S ρ}) (t - τ_{i n f})} + B_{o u t}^{(2)} \exp {- k_{o u t} (t - τ_{i n f})} \end{array}

parameter		value
m ₁ (min⁻¹ )	arterial blood	0.179 *
m ₂ (min⁻¹ )	arterial blood	0.0104 *
A ₁ (µM)	arterial blood	41 **
A ₂ (µM)	arterial blood	0
τ_inf (min)	arterial blood	25
S_inf (µMmin⁻¹ )	arterial blood	1.64 **
F_pρ (min⁻¹ )	all tissues	0.05
PSρ (min⁻¹ )	fatty tissue parenchyma carcinoma	0.67∙10⁻⁴ 1.0∙10⁻⁴ 2.0∙10⁻⁴
k_out (min⁻¹ )	all tissues	1.67∙10⁻³
v_p	fatty tissue parenchyma carcinoma	0.02 * 0.04 * 0.04 ***

Coefficients
infusion period $0 \leq t \leq τ_{i n f}$		wash-out period $t \geq τ_{i n f}$
$A_{0} = \frac{S_{\inf}}{k_{e \lim}} \frac{k_{F}}{k_{F} + k_{p}^{P S ρ}}$
$A_{m 1}^{(1)} = \frac{S_{\inf}}{k_{e l i m}} \frac{k_{F} q}{k_{F} + k_{p}^{P S ρ} - m_{1}}$		$A_{m 1}^{(2)} = A_{m 1}^{(1)} {1 - \exp (- m_{1} τ_{i n f})}$
$A_{m 2}^{(1)} = \frac{S_{\inf}}{k_{e l i m}} \frac{k_{F} (1 - q)}{k_{F} + k_{p}^{P S ρ} - m_{2}}$		$A_{m 2}^{(2)} = A_{m 2}^{(1)} {1 - \exp (- m_{2} τ_{i n f})}$
$A_{F}^{(1)} = A_{m 1}^{(1)} + A_{m 2}^{(1)} - A_{0}$		$A_{F}^{(2)} = A_{m 1}^{(2)} + A_{m 2}^{(2)} - C_{p} (τ_{i n f})$
$B_{0} = A_{0} \frac{k_{e}^{P S ρ}}{k_{o u t}}$

$B_{m 1}^{(i)} = \frac{k_{e}^{P S ρ}}{m_{1} - k_{o u t}} A_{m 1}^{(i)}$ (i = 1, 2) $B_{m 2}^{(i)} = \frac{k_{e}^{P S ρ}}{m_{2} - k_{o u t}} A_{m 2}^{(i)}$ (i = 1, 2)

$B_{o u t}^{(1)} = B_{0} + B_{m 1}^{(1)} + B_{m 2}^{(1)} - f_{o u t} A_{F}^{(1)}$		$B_{o u t}^{(2)} = C_{e} (τ_{i n f}) + B_{m 1}^{(2)} + B_{m 2}^{(2)} - f_{o u t} A_{F}^{(2)}$
Abbreviations
$q = \frac{A_{1} m_{2}}{A_{1} m_{2} + A_{2} m_{1}}$ $k_{e l i m} = \frac{(A_{1} + A_{2}) m_{1} m_{2}}{A_{1} m_{2} + A_{2} m_{1}}$ $f_{o u t} = \frac{k_{e}^{P S ρ}}{k_{F} + k_{p}^{P S ρ} - k_{o u t}}$

parameter		value
m ₁ (min⁻¹ )	arterial blood	0.179 *
m ₂ (min⁻¹ )	arterial blood	0.0104 *
A ₁ (µM)	arterial blood	41 **
A ₂ (µM)	arterial blood	0
τ_inf (min)	arterial blood	25
S_inf (µMmin⁻¹ )	arterial blood	1.64 **
F_pρ (min⁻¹ )	all tissues	0.05
PSρ (min⁻¹ )	fatty tissue parenchyma carcinoma	0.67∙10⁻⁴ 1.0∙10⁻⁴ 2.0∙10⁻⁴
k_out (min⁻¹ )	all tissues	1.67∙10⁻³
v_p	fatty tissue parenchyma carcinoma	0.02 * 0.04 * 0.04 ***

Coefficients
infusion period $0 \leq t \leq τ_{i n f}$		wash-out period $t \geq τ_{i n f}$
$A_{0} = \frac{S_{\inf}}{k_{e \lim}} \frac{k_{F}}{k_{F} + k_{p}^{P S ρ}}$
$A_{m 1}^{(1)} = \frac{S_{\inf}}{k_{e l i m}} \frac{k_{F} q}{k_{F} + k_{p}^{P S ρ} - m_{1}}$		$A_{m 1}^{(2)} = A_{m 1}^{(1)} {1 - \exp (- m_{1} τ_{i n f})}$
$A_{m 2}^{(1)} = \frac{S_{\inf}}{k_{e l i m}} \frac{k_{F} (1 - q)}{k_{F} + k_{p}^{P S ρ} - m_{2}}$		$A_{m 2}^{(2)} = A_{m 2}^{(1)} {1 - \exp (- m_{2} τ_{i n f})}$
$A_{F}^{(1)} = A_{m 1}^{(1)} + A_{m 2}^{(1)} - A_{0}$		$A_{F}^{(2)} = A_{m 1}^{(2)} + A_{m 2}^{(2)} - C_{p} (τ_{i n f})$
$B_{0} = A_{0} \frac{k_{e}^{P S ρ}}{k_{o u t}}$

$B_{m 1}^{(i)} = \frac{k_{e}^{P S ρ}}{m_{1} - k_{o u t}} A_{m 1}^{(i)}$ (i = 1, 2) $B_{m 2}^{(i)} = \frac{k_{e}^{P S ρ}}{m_{2} - k_{o u t}} A_{m 2}^{(i)}$ (i = 1, 2)

$B_{o u t}^{(1)} = B_{0} + B_{m 1}^{(1)} + B_{m 2}^{(1)} - f_{o u t} A_{F}^{(1)}$		$B_{o u t}^{(2)} = C_{e} (τ_{i n f}) + B_{m 1}^{(2)} + B_{m 2}^{(2)} - f_{o u t} A_{F}^{(2)}$
Abbreviations
$q = \frac{A_{1} m_{2}}{A_{1} m_{2} + A_{2} m_{1}}$ $k_{e l i m} = \frac{(A_{1} + A_{2}) m_{1} m_{2}}{A_{1} m_{2} + A_{2} m_{1}}$ $f_{o u t} = \frac{k_{e}^{P S ρ}}{k_{F} + k_{p}^{P S ρ} - k_{o u t}}$